MarketBeat
13 Sept 2026, 14:50 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Capricor Therapeutics (CAPR) faces an FDA PDUFA action date on November 22, 2026, for its Duchenne Muscular Dystrophy drug Deramiocel. — FDA approval is a binary catalyst that could lead to massive valuation swings, especially given the 230% analyst upside target.
+0.90Kodiak Sciences (KOD) expects results from its Phase 3 DAYBREAK study for wet AMD treatments between September and December 2026. — Positive results are described as 'make-or-break' for the company and critical to mitigating its widening net losses.
+0.80Invivyd (IVVD) is awaiting analysis results from its Phase 3 DECLARATION study for VYD2311, a next-generation COVID-19 prophylaxis. — Successful results would expand the company's commercial label and potentially trigger a significant move from its current penny-stock valuation.
+0.70Continue reading
5 related stories
Search tags
Kodiak Sciences' Q2 2026 net loss widened to $65.6 million, with current cash reserves of $125.9 million expected to last into 2027. — Increasing burn rates and declining working capital create significant financial risk if clinical catalysts fail.
-0.40Which stocks this story touches
The company has a commercially available product, FDA Fast Track designation for a new trial, and significant analyst price target upside.
The company has a very high analyst price target upside despite a minor FDA review delay.
Positive analyst price targets and upcoming Phase 3 results are offset by widening net losses and declining working capital.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
4h ago
